metastatic breast cancer treatment

The priority review is granted for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The drug will be made available in three strengths i.e. – 125 mg, 100 mg and 75 mg capsules priced at Rs 3,150 for 75 mg; Rs 3,600…